Efficacy of Checkpoint Inhibitors in Neuroendocrine Neoplasms
| Autor: | Timothy J. Hobday, Patrick W. McGarrah, Thorvardur R. Halfdanarson, Jennifer Gile, Rachel A. Eiring, Jason S. Starr, Mohamad Bassam Sonbol, Alex J. Liu |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male Oncology Thyroiditis medicine.medical_specialty Future studies Endocrinology Diabetes and Metabolism Immune checkpoint inhibitors medicine.medical_treatment Neuroendocrine tumors Young Adult 03 medical and health sciences 0302 clinical medicine Endocrinology Internal medicine Antineoplastic Combined Chemotherapy Protocols Internal Medicine Humans Medicine In patient Immune Checkpoint Inhibitors Objective response Aged Aged 80 and over Hepatology Cytotoxins business.industry Poorly differentiated Immunotherapy Middle Aged medicine.disease Hospitals Progression-Free Survival Confidence interval Pancreatic Neoplasms Neuroendocrine Tumors Treatment Outcome 030220 oncology & carcinogenesis Female 030211 gastroenterology & hepatology Neoplasm Grading business |
| Zdroj: | Pancreas. 50:500-505 |
| ISSN: | 1536-4828 0885-3177 |
| Popis: | Objectives Checkpoint inhibitors (CPIs) for low- and intermediate-grade neuroendocrine tumors (NETs) have been associated with limited efficacy; recent studies suggest CPIs may represent promising treatment for high-grade neuroendocrine neoplasms (NENs). Methods We examined 57 patients with NENs who were treated with CPIs to determine if NETs and neuroendocrine carcinomas (NECs) respond to immunotherapy. Results Patients with poorly differentiated NECs on CPI monotherapy had an objective response rate (ORR) of 0% and median progression-free survival (PFS) of 2.1 months (95% confidence interval [CI], 0.5-4.6). Patients with poorly differentiated NECs on dual CPI therapy had an ORR of 13% and PFS of 3.5 months (95% CI, 1.4-not reached [NR]). Patients with poorly differentiated NECs on CPI and cytotoxic therapy had an ORR of 36% with PFS of 4.2 months (95% CI, 1.6-NR). Well-differentiated grade 1 and 2 NETs on CPI monotherapy had an ORR of 25% with PFS NR. Well-differentiated grade 3 NETs had 0% ORR with a PFS of 2.9 months (95% CI, 1.4-4.2) on CPI monotherapy. Conclusions Checkpoint inhibitor therapy shows limited activity in patients with NENs. Future studies should identify biomarkers that can help identify patients who are likely responders to immunotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|